The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Latest News From
The World of Cardiology
Explore the blog
Despite the Coronavirus COVID-19 Pandemic, we are open for our patients
As a healthcare provider we allowed to serve our existing patients as well as anyone else who may have symptoms that suggest heart disease. We have safeguarded both our patients and staff against infection from Coronavirus whilst still providing the consultations and diagnostics.
Posted on 25 November 2011